multiple sclerosis:
Personalised Cellular treatment
A structured, physician-led program designed to stabilise neurological function, aim to stop disease progression and inflammatory activity, and improve overall quality of life through continuous medical supervision and personalised therapeutic strategies.
Targeting MS
at Every Stage
Multiple Sclerosis (MS) is treated at all stages of the disease, with therapeutic protocols individually adapted to disease activity, progression pattern and functional status.
Regenerative and cellular therapy targets the core biological mechanisms driving MS, including chronic neuroinflammation, immune dysregulation and ongoing damage to neural signaling and myelin integrity.
Applied as a structured and adjustable medical program, therapy allows intervention at early, progressive and advanced stages of MS, with the objective of stabilising neurological function, aiming to stop disease activity and progression, improving daily performance and extending long-term functional stability, even as the disease evolves.
Understanding
Cellular Therapy
Cellular therapy is a medical approach that uses living cells to influence how the body responds to disease.
These cells do not replace organs or tissues. Instead, they interact with the immune and nervous systems, helping regulate inflammation, support damaged tissues and improve how the body functions at a cellular level.
Rather than acting as a one-time intervention, cellular therapy works by modifying the biological environment in which the disease progresses.
By modulating immune regulation and inflammatory activity, cellular therapy can support meaningful functional improvement, symptom stabilisation and the activation of the body’s own recovery mechanisms.
Key Therapeutic Advantages
no surgery
Stem cell therapy is delivered through precisely controlled local or intravenous administration of a biomedical cell product.
The procedure is performed using specialised medical infusion systems and fine needles, without the need for surgical instruments or operative intervention.
No General Anesthesia Required
Treatment does not require general anesthesia.
This is particularly important for elderly patients, individuals with neurological conditions, or those for whom anesthesia may pose additional medical risks.
Minimal Recovery Time
The procedure requires no special preparation and does not disrupt the patient’s daily routine.
Its non-surgical nature and absence of general anesthesia allow for a short and well-tolerated recovery period.
No risk of rejection
When clinically appropriate, therapy may involve the use of the patient’s own autologous cells, which are generally well tolerated and associated with a low risk of immune reactions.
In cases where autologous therapy is not feasible, carefully selected allogeneic cellular therapies may be applied within strict medical protocols, providing a safe and effective option for specific clinical indications.
Components of the
BioCells MS Program
Mesenchymal
Stem Cells (MSCs)
Mesenchymal stem cells (MSCs) are multipotent regenerative cells obtained from carefully selected and certified tissue sources.
In Multiple Sclerosis, MSCs are used for their ability to modulate immune-mediated neuroinflammation, support remyelination processes, protect neural structures and preserve neurological function.
Depending on clinical indications, MSCs are obtained either from the patient’s own bone marrow (approximately 50 ml, collected under local anesthesia) or from certified donor-derived sources. All cells are isolated, expanded and prepared in a controlled laboratory environment to reach therapeutic concentration.
By strengthening neural resilience, regulating inflammatory activity and supporting repair mechanisms within the central nervous system, MSC-based therapy aims to stop disease activity and functional decline, enhance neurological performance and support long-term functional stability and quality of life.
Components of the
BioCells MS Program
T-regulatory cells
(T-regs)
T-regulatory cells (T-regs) are specialised immune cells responsible for maintaining immune balance and preventing excessive or destructive inflammatory responses, particularly within the central nervous system.
In Multiple Sclerosis, T-regs play a critical role in suppressing autoimmune-driven attacks against myelin and neural tissue, limiting chronic inflammation in the brain and spinal cord that leads to demyelination and neurological dysfunction.
At BioCells Medical, T-reg therapy is delivered through a personalised protocol based on either autologous cells (patient-derived) or carefully selected allogeneic cells (donor-derived), depending on clinical indications, immune profile and disease activity. The objective is to precisely recalibrate immune regulation and restore long-term neuro-immune stability.
Through targeted immune recalibration, T-reg therapy is designed to stop immune-driven disease activity and functional deterioration, stabilise neurological function and reduce symptom burden, including spasticity, fatigue, sensory disturbances and mobility impairment in selected patients.
Components of the
BioCells MS Program
Purified concentrated
exosomes
Purified exosomes are nanoscale biological vesicles naturally released by regenerative cells, containing concentrated growth factors, regulatory proteins and micro-RNAs involved in cellular repair and intercellular communication.
In Multiple Sclerosis, exosomes function as molecular messengers that influence key disease-related processes by reducing oxidative stress, modulating inflammatory signaling and supporting metabolic activity within affected neural and glial cells.
At BioCells Medical, exosomes are produced in our laboratory as highly purified, concentrated formulations, ensuring consistent bioactivity, controlled composition and a high safety profile prior to clinical application.
Acting at a molecular level, purified exosomes are designed to interrupt ongoing micro-inflammatory and degenerative signaling, improve neural efficiency and metabolic resilience, and enhance coordination, endurance and neurological responsiveness — contributing to measurable functional improvement and sustained stability across different stages of MS.
Components of the
BioCells MS Program
Personalised Neurostimulation Therapy
Neurostimulation is a non-invasive medical technology that delivers precisely controlled electrical impulses to targeted regions of the brain and spinal cord.
In Multiple Sclerosis, neurostimulation is used to enhance neural conductivity, reactivate functionally suppressed pathways and improve signal transmission across demyelinated or compromised neural networks.
At BioCells Medical, neurostimulation is integrated into a personalised therapeutic protocol and applied according to the patient’s neurological profile, functional deficits and disease activity, with the goal of optimising neural responsiveness and reinforcing functional recovery.
By modulating neural circuits and restoring more physiological signaling patterns, neurostimulation aims to stop progressive loss of motor control and coordination, improve balance, gait and muscle synchronisation, and restore a stronger sense of body stability and voluntary functional control.
Components of the
BioCells MS Program
Peptide-Based
Protocol
Peptide therapy utilises precisely engineered biological molecules that function as cell-to-cell messengers, restoring disrupted communication within the nervous and immune systems.
In Multiple Sclerosis, targeted peptides are applied to optimise mitochondrial function, support cellular energy production and protein synthesis, and regulate metabolic and inflammatory pathways that contribute to neurodegeneration and fatigue.
At BioCells Medical, peptide therapy is incorporated into a personalised therapeutic plan through custom-tailored formulations, selected according to the patient’s metabolic profile, neurological status and disease activity, with the objective of reinforcing long-term neuroprotective and metabolic stability.
By optimising cellular signaling and energy regulation, peptide therapy aims to stop metabolic-driven functional decline, reduce fatigue-related limitations, enhance muscle endurance and cognitive clarity, and maintain sustained energy balance — strengthening overall neurological performance and daily functional capacity.
Comprehensive Medical Rehabilitation
Following treatment, patients enter a structured medical rehabilitation and follow-up phase.
Each patient is supervised by a dedicated rehabilitation specialist who monitors recovery, functional status and overall well-being, providing individual recommendations and ongoing medical guidance.
Objective health data collected through a medical-grade wristband supports clinical decision-making, allowing continuous assessment of recovery dynamics and quality-of-life indicators.
SAFE FOR
EVERY stage OF LIFE
The treatment program is delivered as a non-surgical, physician-led approach under continuous medical supervision.
All therapies are individually adjusted according to the patient’s clinical condition, disease stage and age, with safety continuously prioritised throughout the treatment process.
Expected Outcomes
-
Stopping of disease activity and functional decline, with improved motor control, coordination and daily mobility
-
Marked improvement in neuromuscular performance, including stronger voluntary movements, better limb coordination and increased physical endurance
-
Preservation and improvement of speech and swallowing function, supporting clearer communication and safer, more efficient feeding
-
Improved balance, gait stability and postural control, contributing to greater physical confidence and reduced fall risk
-
Reduction and improved control of spasticity, muscle stiffness and involuntary muscle tension, allowing smoother, more purposeful movement
-
Restoration of physical energy and resilience, with improved tolerance to daily activities and reduced fatigue-related limitations
-
Enhanced cognitive clarity and neurological responsiveness, supporting attention, processing speed and mental stamina
-
Meaningful improvement in quality of life and functional independence, including in progressive forms of Multiple Sclerosis
Clinical outcomes may vary depending on disease stage, individual biological characteristics and treatment response.
Selected Clinical and Scientific References
-
Allogeneic Mesenchymal Stem Cell–Derived Exosome Therapy for Progressive Multiple Sclerosis
https://clinicaltrials.gov/study/NCT07146087 -
Monitoring of Outcomes of Cellular and Exosome-based Therapies in Autoinflammatory and Post-infectious Neuroinflammatory Syndromes
https://clinicaltrials.gov/study/NCT07145502 -
Neural Stem Cell Transplantation in Patients with Progressive Multiple Sclerosis: an Open-Label, Phase 1 Study
https://pubmed.ncbi.nlm.nih.gov/36624312/ -
Mesenchymal Stem Cells for Multiple Sclerosis: A Systematic Review
https://pubmed.ncbi.nlm.nih.gov/35008235/ -
Stem Cell Therapy in Multiple Sclerosis: Current Evidence and Future Perspectives
https://pubmed.ncbi.nlm.nih.gov/33217577/ -
Modelling Multiple Sclerosis Using Induced Pluripotent Stem Cells
https://pubmed.ncbi.nlm.nih.gov/33130461/
Journey to Recovery
Starts Here
Personalised regenerative treatment designed around you.